Analysis of biomarkers reveals major clinical implications for stroke and brain ischemia, suggesting broader use.
During the analysis of results of research of various biomarkers at 50 patients with stroke, at 40 patients with brain ischemia owing to an atherosclerosis carotid arteries, at 30 patients with epilepsy syndromes, at 20 children born by mothers-addicts, the conclusion about the big clinical importance of such biomarkers, as PARK7 and nucleoside diphosphate kinase A, S-100b, Acetylpolyamine oxidase [AcPAO], S-jet fiber, GluRI an AMPA-receptor, autoantibodies (aAbs) to opiate and glutamate to receptors (type AMPA and glutamate to receptors NMDA, NmDa- autoantibodies, NR1, NR-2A-NR2D and NR3A) which help early diagnostics of pathological process, its degree of expressiveness and dynamics under the influence of therapeutic actions is made. Wide introduction in clinical practice of biomarkers is recommended: NR1, NR-2A-NR2D and NR3A, GluRI an AMPA-receptor. Literary data about genetic and biochemical markers is cited at degenerate diseases of nervous system, at Alzheimer's and Parkinson's diseases.
No takes yet. Share an insight, caveat, or question.
Skoromets et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: